Regeneron Pharmaceuticals (REGN) earnings

Earnings (net income) · fiscal 2025
$4.50B

Regeneron Pharmaceuticals (REGN) reported net income of $4.50B in fiscal 2025 (the year ended December 31, 2025). That is 2.1% higher than the $4.41B of fiscal 2024. Figures as of 18 Nov 2026, 10:26 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Earnings (net income), fiscal 2025
$4.50B
Change on fiscal 2024
+2.1%
Growth, 5 years
+5.1% a year
Growth, 10 years
+21.6% a year
Highest on record
$8.08Bfiscal 2021
Lowest on record
-$221.76Mfiscal 2011
Fiscal years on record
182008–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Regeneron Pharmaceuticals earnings, in more detail

Over the five fiscal years to 2025 net income grew at a compound 5.1% a year; over ten years the rate was 21.6% a year. Across the 18 fiscal years on record (2008–2025), the highest was $8.08B in fiscal 2021 and the lowest -$221.76M in fiscal 2011.

History · 18 fiscal years

Earnings (net income) by fiscal year

Regeneron Pharmaceuticals earnings, year by year

Regeneron Pharmaceuticals (REGN) earnings by fiscal year
Fiscal yearEarnings (net income)ChangeYear ended
2025$4.50B 2.1% up
2024$4.41B 11.6% up
2023$3.95B 8.9% down
2022$4.34B 46.3% down
2021$8.08B 129.9% up
2020$3.51B 66.0% up
2019$2.12B 13.4% down
2018$2.44B 104.0% up
2017$1.20B 33.8% up
2016$895.50M 40.8% up
2015$636.06M 88.1% up
2014$338.13M 18.3% down
2013$413.74M 44.9% down
2012$750.27M—
2011-$221.76M—
2010-$104.47M—
2009-$67.83M—
2008-$79.13M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Earnings here means net income: what is left of the year's revenue after every cost, interest and tax, as reported on the income statement.

How to read it

Compare it across years rather than in isolation — one-off gains and write-downs can swing a single year a long way.

Earnings (net income) at health care companies of similar size

Earnings (net income) of Regeneron Pharmaceuticals and comparable companies
CompanyEarnings (net income)Fiscal year
Moderna MRNA-$2.82B2025
CVS Health CVS$1.77B2025
HCA Healthcare HCA$6.78B2025
GSK GSK£5.72B2025
Regeneron Pharmaceuticals REGN$4.50B2025
Elevance Health ELV$5.66B2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on REGN

Regeneron Pharmaceuticals, figure by figure

Regeneron Pharmaceuticals (REGN) overview: price, valuation and scorecardAll health care companies by market value

Regeneron Pharmaceuticals earnings: questions and answers

What is Regeneron Pharmaceuticals's net income?

Regeneron Pharmaceuticals (REGN) reported net income of $4.50B in fiscal 2025 (the year ended December 31, 2025). That is 2.1% higher than the $4.41B of fiscal 2024.

What is the growth rate of Regeneron Pharmaceuticals's net income?

Over the five fiscal years to 2025 net income grew at a compound 5.1% a year; over ten years the rate was 21.6% a year.

What are the highest and lowest net income figures on record for Regeneron Pharmaceuticals?

Across the 18 fiscal years on record (2008–2025), the highest was $8.08B in fiscal 2021 and the lowest -$221.76M in fiscal 2011.

How is Regeneron Pharmaceuticals's net income calculated?

Earnings here means net income: what is left of the year's revenue after every cost, interest and tax, as reported on the income statement. For Regeneron Pharmaceuticals it is on record here for 18 fiscal years, 2008 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Regeneron Pharmaceuticals (REGN) earnings”, data as of 18 November 2026. https://funkfolio.com/stock/REGN/earnings

Underlying data: the company's filings with the SEC and Yahoo Finance.